Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. News
Mirati Therapeutics, Inc. Quantitative Score
About Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Mirati Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Mirati Therapeutics, Inc. Financials
Table Compare
Compare MRTX metrics with: | |||
|---|---|---|---|
Earnings & Growth | MRTX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MRTX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MRTX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MRTX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Mirati Therapeutics, Inc. Income
Mirati Therapeutics, Inc. Balance Sheet
Mirati Therapeutics, Inc. Cash Flow
Mirati Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Sell |
| Return on Assets | Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Mirati Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. James G. Christensen Ph.D. | Executive Vice President & Chief Scientific Officer |
| Mr. David D. Meek | Chief Executive Officer & Director |
| Mr. Benjamin J. Hickey M.B.A. | Chief Commercial Officer |
| Ms. Laurie D. Stelzer M.B.A. | Consultant |
| Ms. Laurie D. Stelzer | Chief Financial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. James G. Christensen Ph.D. | Executive Vice President & Chief Scientific Officer | 1968 | 1.76M | |
| Mr. David D. Meek | Chief Executive Officer & Director | Male | 1963 | 1.66M |
| Mr. Benjamin J. Hickey M.B.A. | Chief Commercial Officer | Male | 1975 | 769.03K |
| Ms. Laurie D. Stelzer M.B.A. | Consultant | Female | 1968 | 609.06K |
| Ms. Laurie D. Stelzer | Chief Financial Officer | Female | 1968 | 609.06K |
Mirati Therapeutics, Inc. Insider Trades
| Date | 23 Jan |
| Name | Boxer Capital, LLC |
| Role | See remarks |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 30518 |
| Date | 23 Jan |
| Name | Boxer Capital, LLC |
| Role | See remarks |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 1413475 |
| Date | 23 Jan |
| Name | Sharp Shalini |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 4162 |
| Date | 23 Jan |
| Name | Sharp Shalini |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 5252 |
| Date | 23 Jan |
| Name | Sharp Shalini |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 6808 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 23 Jan | Boxer Capital, LLC | See remarks | Disposed | D-Return | 30518 |
| 23 Jan | Boxer Capital, LLC | See remarks | Disposed | D-Return | 1413475 |
| 23 Jan | Sharp Shalini | Director | Disposed | D-Return | 4162 |
| 23 Jan | Sharp Shalini | Director | Disposed | D-Return | 5252 |
| 23 Jan | Sharp Shalini | Director | Disposed | D-Return | 6808 |